Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antimalarials - GlaxoSmithKline/MMV

Drug Profile

Research programme: antimalarials - GlaxoSmithKline/MMV

Alternative Names: Amodiaquine analogues - GlaxoSmithKline/MMV; Azithromycin-based antimalarials - GlaxoSmithKline/MMV; carboxamides - GlaxoSmithKline/MMV; Cysteine protease inhbitors - GlaxoSmithKline/MMV; Enoyl-ACP reductase inhibitors - GlaxoSmithKline/MMV; GSK-369796; GW 308678; Isoquine analogues - GlaxoSmithKline/MMV

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Medicines for Malaria Venture
  • Developer GlaxoSmithKline; Medicines for Malaria Venture; University of California at San Francisco
  • Class Aminoquinolines; Erythromycins; Pyridones
  • Mechanism of Action Cysteine endopeptidase inhibitors; Dihydroorotate dehydrogenase inhibitors; Electron transport complex I inhibitors; Enoyl-ACP reductase inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in Spain
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Malaria in USA
  • 18 Apr 2011 Preclinical development is ongoing in the US and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top